Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM
Summary
Acoramidis demonstrated reversal of cardiac structural disease progression and functional decline through 42 months in ATTR-CM patients, with up to half showing clinically meaningful cardiac function improvement and significantly increased hospitalization-free days. This represents the first therapy potentially showing reversal of cardiac structural disease in this patient population.
Clinical Trial Data
Met
Outcome Details
Acoramidis demonstrated reversal of cardiac structural disease progression and functional decline through 42 months with up to half of patients showing clinically meaningful improvement in cardiac function; significantly increased days alive and free from hospitalization
Read the original article
Published by GlobeNewswire Clinical Studies on August 30, 2026 2:00 PM